This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by König, H.-H.
Right arrow Articles by Barry, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by König, H.-H.
Right arrow Articles by Barry, J.-C.
Related Collections
Right arrow Ophthalmology
PEDIATRICS Vol. 113 No. 2 February 2004, pp. e95-e108

ELECTRONIC ARTICLE

Cost-Utility Analysis of Orthoptic Screening in Kindergarten: A Markov Model Based on Data From Germany

Hans-Helmut König, MD, MPH* and Jean-Cyriaque Barry, MD{ddagger}

* Health Economics Research Unit, Department of Psychiatry, University of Leipzig, Leipzig, Germany
{ddagger} Department of Ophthalmology II, University Eye Hospital Tübingen, Tübingen, Germany

Objective. To estimate the long-term cost-effectiveness of a hypothetical screening program for untreated amblyopia in 3-year-old children conducted by orthoptists in all German kindergartens in the year 2000.

Methods. A cost-utility analysis was performed for which a decision tree was combined with a Markov model. Incremental costs and effects during the children’s remaining lifetime were estimated. The model took into account the probability of treatment without screening, age-specific treatment success rates, costs of screening and treatment, as well as effects of unilateral and bilateral visual impairment caused by amblyopia and other eye diseases coming along later in life on quality of life (utility). Model parameter values were obtained from a field study of orthoptic screening in kindergarten, from the literature, and from expert interviews. Costs were estimated from a third-party payer perspective. Uncertainty was assessed by univariate and probabilistic sensitivity analysis (Monte Carlo simulation).

Results. The incremental cost-effectiveness ratio (ICER) of orthoptic screening was 7397 Euro ({euro}) per quality-adjusted life year (QALY) when costs and effects were discounted at 5%. In univariate sensitivity analysis, the ICER was sensitive to the uncertainty regarding the utility of unilateral visual impairment and to the discount rate for effects; besides uncertainty regarding the prevalence of untreated amblyopia, the odds ratio of success of treatment when started late, and the probability of treatment without screening had a noticeable but much smaller effect. Monte Carlo simulation yielded a 90% uncertainty interval for the ICER of 3452 {euro}/QALY to 72 637 {euro}/QALY; the probability of an ICER <25 000 {euro}/QALY was 84%.

Conclusions. The ICER of orthoptic screening seems to fall within a range that warrants careful consideration by decision-makers. Much of the uncertainty in results comes from the uncertainty regarding the effect of amblyopia on quality of life. To reduce this uncertainty, the impact of amblyopia on utility should be investigated.

Key Words: amblyopia • vision screening • children • preschool • cost-effectiveness • decision modeling • Markov process

Abbreviations: VA, visual acuity • QALY, quality-adjusted life year • ICER, incremental cost-effectiveness ratio • CI, confidence interval • OR, odds ratio • BMES, Australian Blue Mountain Eye Study

Received for publication May 15, 2003; Accepted Oct 20, 2003.




This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
J. Nilsson
The Burden of Amblyopia and Strabismus: Justification of Treatment and Screening Revisited
Arch Ophthalmol, January 1, 2008; 126(1): 143 - 145.
[Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
J. Nilsson
The negative impact of amblyopia from a population perspective: untreated amblyopia almost doubles the lifetime risk of bilateral visual impairment
Br. J. Ophthalmol., November 1, 2007; 91(11): 1417 - 1418.
[Full Text] [PDF]